Vigabatrin: Vigabatrin new ST formulation then Sabril® ( DrugBank: Vigabatrin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 145 | West syndrome | 1 |
145. West syndrome
Clinical trials : 43 / Drugs : 54 - (DrugBank : 15) / Drug target genes : 27 - Drug target pathways : 24
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02220114 (ClinicalTrials.gov) | May 2014 | 14/8/2014 | Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy | Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy. Observational, Descriptive, Open-label, Multi-centric, Non-randomized Study | Infantile Spasms | Drug: Vigabatrin: Vigabatrin new ST formulation then Sabril® | Orphelia Pharma | Institut National de la Santé Et de la Recherche Médicale, France;Hospices Civils de Lyon;National Research Agency, France | Completed | 1 Month | 6 Years | All | 38 | N/A | France |